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Aims Increased Ankyrin Repeat Domain 1 (ANKRD1) levels linked to gain of function mutations have been associated to
total anomalous pulmonary venous return and adult cardiomyopathy occurrence in humans. The link between in-
creased ANKRD1 level and cardiac structural and functional disease is not understood. To get insight into this
problem, we have generated a gain of function ANKRD1 mouse model by overexpressing ANKRD1 in the
myocardium.
....................................................................................................................................................................................................
Methods
and results
Ankrd1 is expressed non-homogeneously in the embryonic myocardium, with a dynamic nucleo-sarcomeric
localization in developing cardiomyocytes. ANKRD1 transgenic mice present sinus venosus defect, which originates
during development by impaired remodelling of early embryonic heart. Adult transgenic hearts develop diastolic
dysfunction with preserved ejection fraction, which progressively evolves into heart failure, as shown histologically
and haemodynamically. Transgenic cardiomyocyte structure, sarcomeric assembly, and stability are progressively im-
paired from embryonic to adult life. Postnatal transgenic myofibrils also present characteristic functional alterations:
impaired compliance at neonatal stage and impaired lusitropism in adult hearts. Altogether, our combined analyses
suggest that impaired embryonic remodelling and adult heart dysfunction in ANKRD1 transgenic mice present a
common ground of initial cardiomyocyte defects, which are exacerbated postnatally. Molecular analysis showed
transient activation of GATA4-Nkx2.5 transcription in early transgenic embryos and subsequent dynamic transcrip-
tional modulation within titin gene.
....................................................................................................................................................................................................
Conclusions ANKRD1 is a fine mediator of cardiomyocyte response to haemodynamic load in the developing and adult heart.
Increased ANKRD1 levels are sufficient to initiate an altered cellular phenotype, which is progressively exacerbated
into a pathological organ response by the high ventricular workload during postnatal life. Our study defines for the
first time a unifying picture for ANKRD1 role in heart development and disease and provides the first mechanistic
link between ANKRD1 overexpression and cardiac disease onset.
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1. Introduction
Ankyrin Repeat Domain 1 (ANKRD1, also known as Cardiac Ankyrin
Repeat Protein, CARP) is a member of the muscle-specific ankyrin re-
peat proteins (MARP) family, which also includes ANKRD2/Arpp and
DARP.1,2 MARP proteins are involved in muscle stress response and are
structurally characterized by four ankirin repeats, a coiled-coil domain, a
nuclear localization signal, and a PEST degradation sequence, which
mediates its rapid turnover via the ubiquitin-proteasome pathway.3,4
ANKRD1 is highly expressed during heart development and down-
regulated in adult life.5–7 In the developing heart, ANKRD1 has been pro-
posed to work as transcriptional cofactor and negative regulator of
myocardial gene expression.5–7 ANKRD1 is a target of Nkx2.5 in vivo5
and its promoter can be cooperatively activated by Nkx2.5 and GATA4.6
In adult cardiomyocytes, ANKRD1 is normally located at the sarco-
mere, but it has been shown to translocate to the nucleus upon
mechanical stimulation in vitro.2 In the sarcomere, ANKRD1 is found at
the I-band where it is a component of titin N2A-linked signalling com-
plex.2,8 Physical interaction between ANKRD1 and titin N2A spring do-
main has been shown to reduce PKA phosphorylation and titin
compliance.1 ANKRD1 has additionally been shown to functionally in-
teract with GATA4 in the I band and the nucleus, thereby modulating
GATA4-mediated sarcomeric gene expression and sarcomeric organiza-
tion.9,10 Interactions with several additional partners involved in modula-
tion of muscle structure and function have been reported.3,8 ANKRD1 is
therefore part of a stretch-sensing unit capable of relaying biomechanical
stress signals to the regulation of gene expression. In line, ANKRD1 ex-
pression is up-regulated in response to hypertrophy and in heart failure
(HF).6,11–13 However, the absence of cardiac phenotype in ANKRD1
knock-out mouse models,10,14 combined with contradictory results
from loss and gain of function approaches,3,9,15,16 have precluded a clear
understanding of ANKRD1 role in adult heart.
Graphical Abstract
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Genetic mutations in ANKRD1, mostly associated to a gain of function
condition, have been correlated to several types of cardiac disease in
humans. ANKRD1 missense mutations have been identified in patients
with hypertrophic and dilated cardiomyopathy (HCM, DCM).17–19
ANKRD1 has additionally been identified as a candidate gene for total
anomalous pulmonary venous return (TAPVR) in isolated patients.20,21
TAPVR is a congenital heart disease (CHD) which affects 1:15 000 live
births and is characterized by incorrect pulmonary vein (PV) drainage
into the heart.22 TAPVR leads to high mortality rate in the first year of
life, unless surgically corrected. Reported TAPVR patients presented
either chromosomal rearrangement or T116M–ANKRD1 mutation,
leading respectively to a three- to four-fold increase in ANKRD1 tran-
script levels or 10–20% increase in protein stability,4,21 suggesting that
ANKRD1 expression levels must be tightly regulated during
embryogenesis.
Here, we show that Ankrd1 is heterogeneously expressed in the de-
veloping heart, with a dynamic nucleo-sacroplasmic sublocalization.
Myocardial-overexpressing ANKRD1 transgenic (Tg) mice are born
with congenital sinus venosus (SV) defect. In postnatal life, diastolic dys-
function and progressive transition from adaptive to maladaptive
response occurs. Increased ANKRD1 levels are sufficient to initiate an al-
tered cellular phenotype in the embryonic heart, which is exacerbated
postnatally by high ventricular workload.
2. Methods
2.1 Mouse lines
Human wt-ANKRD1-FLAG tagged cDNA4 was cloned downstream of
the 5 kb Myh6 promoter.23 Two Tg lines were generated by pronuclear
microinjection of linearized constructs into FVB oocytes. Transgene ex-
pression was characterized by western blotting and immunofluores-
cence (Supplementary material online, Figure S1). Genomic DNA was
PCR-genotyped from tails of anaesthetized mice (Zoletil, 30 mg/kg, i.p)
or the amniotic sac of embryos isolated after sacrifice by cervical disloca-
tion of the anaesthetized mother. Isolated embryos, neonatal, and adult
hearts were isolated and processed using standard procedures for sub-
sequent histological, biochemical, or molecular analysis. Animal proce-
dures used conformed to the guidelines from Directive 2010/63/EU of
the European Parliament on the protection of animals used for scientific
purposes.
2.2 PCR analysis
RNA isolation, cDNA transcription, and quantitative PCR were con-
ducted using standard procedures. Primers for titin PCR amplification
were selected to avoid regions with repetitive nucleotide sequences and
potential incorrect priming. All primer sequences are available in
Supplementary material online, Table S1.
2.3 Isolated myofibril analysis
Myofibrils were prepared by homogenization of permeabilized strips of
frozen ventricular tissue in relaxing solution on ice.24 Mechanical meas-
urements from myofibrils in isometric conditions were performed
during activation-relaxation cycles achieved by fast solution switching.25
SL-resting tension relations were determined as previously described.26
2.4 Echocardiographic analysis
Transthoracic echocardiography was performed using a high-resolution
echo machine with a 30 Mhz probe (VEVO 2100 Visualsonics). Both
males and females mice were analysed. Mice were chest shaved and
anaesthetized with 3% isoflurane, and temperature controlled anaesthe-
sia was maintained with 1.5% isoflurane. Two-dimensional cine loops
and M-mode cine loops of a long-axis view and a short-axis view of the
left ventricle (LV) were recorded. Interventricular septum thickness, left
ventricular internal diameter, and left ventricular posterior wall thickness
were measured in diastole and systole from M-mode long-axis view.
Ejection fraction (EF) and fractional shortening (FS) were automatically
calculated by the machine software.
2.5 Doppler analysis of left ventricular and
PV flow
Doppler analysis of left ventricular flow was performed from the long-
axis B-mode image placing the sample volume in the left ventricle, below
the mitral annulus. Isovolumetric contraction and relaxation times
(IVCT, IVRT) and ejection time (ET) were measured from transmitral
Doppler analysis. Myocardial performance index was calculated using
the following formula: MPI = IVCTþIVRT/ET. E wave, A wave, and E
wave deceleration time (DT) were measured from transmitral Doppler
flow profile.
Doppler analysis of PV flow was performed from a corrected long-
axis B-mode image placing the sample volume just before the entry of
the PV in the left aria (Supplementary material online, Figure S2). The
maximal velocity of PV atrial (a), systolic (s), and diastolic (d) flow waves
were measured.
2.6 Statistical analysis
Data are presented as mean± standard deviation. Comparisons be-
tween groups were performed by Students unpaired t-test, Mann–
Wilcoxon W test, or Wilcoxon signed-rank test where appropriate,
based on experimental design. P< 0.05 was considered statistically
significant.
Detailed methods are available in Supplementary data online.
3. Results
3.1 Ankrd1 is heterogeneously expressed in
the developing myocardium
We initially examined Ankrd1 expression in embryonic hearts. In situ hy-
bridization (ISH) on sections showed that Ankrd1 mRNA is expressed in
the myocardium from E7.5 onwards, although not homogeneously
(Figure 1A).
At the venous pole of the heart, at E10.0 differential Ankrd1 mRNA
levels were observed at the left and right pulmonary ridge and the sinus
horns (white arrows, Figure 1Bb). By E10.5, heterogeneous mRNA stain-
ing was visible also within the developing septum primum (black arrow,
Figure 1Bd), around the PV (white arrowhead, Figure 1Bd) and systemic
veins entrance (red arrowheads, Figure 1Ac and Bd). This expression
profile was maintained at E12.5 (Figure 1Ad and 1Be, f) and E14.5
(Figure 1Bg, h).
Heterogeneous Ankrd1 mRNA expression was detected also within
the compact and trabecular layers of the left and right atrial chambers
(LA, RA) (green arrows, Figure 1Cb, e), and the atrioventricular canal (red
asterisk, Figure 1Bh and Ce). Stronger Ankrd1 expression was visible in
the outflow tract and the right ventricle (Figure 1Ac–e), whereas weaker
and more heterogeneous expression was detected in the LV and the
interventricular septum (yellow arrows, Figure 1Ac, d and Cd, f).
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sion in developing cardiomyocytes (Figure 1D). Subcellular protein locali-
zation was always detected at the sarcomeric I band (Figure 1E);
additional nuclear localization was frequently observed in E10.5 cardio-
myocytes (Figure 1Ea, b) but was no more detectable by E14.5
(Figure 1Ec, d).
3.2 ANKRD1 finely modulates rotation
and remodelling in the early myocardium
We next aimed to assess the effects of a genetically-based increase in
ANKRD1 levels on cardiac structure and functionality. Thus, we gener-
ated two transgenic (Tg) mouse lines overexpressing human ANKRD1
Figure 1 Ankrd1 mRNA and protein expression in cardiac development. (A–C) Ankrd1 mRNA expression in E8.5–E14.5 hearts, ISH analysis. Myocardium
is identified by Mhc transcripts. (A) E8.5 (a, b), E10.5 (c), E12.5 (d), E14.5 (h) hearts, global view. Dotted areas in e are magnified below. (B) Ankrd1 expression
at venous pole of E10 (a, b), E10.5 (c, d), E12.5 (e, f), E14.5 (g, h) embryos. (C) Ankrd1 expression in atrial and ventricular chambers of E10.5 (a–d) and E14.5
(e, f) embryos. (D and E) Ankrd1 protein expression and sub-cellular localization in E10.5 and E14.5 hearts, double immunofluorescence and confocal analy-
sis. (D) E10.5 (a, b) and E14.5 (c, d) hearts, overview pictures. Note heterogeneous reaction of a-Ankrd1 (a, c) vs. a-actinin (b, d) antibody. (E) At E10.5 (a, b)
Ankrd1 presents sarcomeric and nuclear (arrows) co-localization; at E14.5 (c, d) Ankrd1 is exclusively sarcomeric. Note strong (yellow star) or low (white
star) a-Ankrd1 antibody reaction in neighboring cardiomyocytes. avc, atrioventricular canal; ca, common atrium; icv, inferior caval vein; ivs, interventricular
septum; lscv, rscv, left, right superior caval vein; lv, left ventricle; oft: outflow tract; pv, pulmonary vein; r, l-pr: right, left pulmonary ridge; rsh, lsh, right, left si-
nus horn; rv: right ventricle; sp, septum primum; v, primitive ventricle; vv, venous valves. Scale bar: A–C= 100lm; D= 100lm, E= 10lm.
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in the myocardium under Myh6 gene promoter (Supplementary material
online, Figure S1A), which is active from E7.5 onwards.27 Transgene pro-
tein levels were very modest in E10.5 and E14.5 embryos
(Supplementary material online, Figure S1A and B and not shown), but in-
creased, to a similar order of magnitude, in neonatal and 10M Tg hearts
(Supplementary material online, Figure S1A). ANKRD1 transgene pre-
sented always a sarcomeric sub-localization, however, some nuclear sig-
nal was additionally visible in adult Tg hearts (Supplementary material
online, Figure S1C). Preliminary analysis did not reveal phenotypic differ-
ences between the two Tg lines (not shown), thus detailed analysis was
performed on a single line.
We initially investigated early cardiac development. E10.5 Tg hearts
presented well-developed atrial and ventricular chambers, which how-
ever appeared more compressed along the cranio-caudal and dorso-
ventral axes, were laterally displaced and presented a reduced rotational
angle if compared to wt littermates (Figure 2Aa, e). In particular, the sino-
atrial region was more caudally oriented in Tg hearts, similarly to E9.5 wt
embryos (Figure 2Be). Compressed shape and malrotation affected both
internal remodelling and the relative orientation between sino-atrial
myocardium, the flanking dorsal mesocardium, and the proepicardium
(Figure 2Aa, e). This resulted in malpositioning of the developing septum
primum, of the pulmonary ridges, as well as of the sinus horns myocar-
dium, visualized by Tbx18 expression28 (Figure 2Ac, d, g, h). The sinus
horns confluence, which defines the entrance of the cardinal veins into
the sino-atrial region, and the pulmonary pit, delineating the route of
canalization of the PV, were distinct in Tg hearts as in wt embryos.
However, in Tg hearts, a mesh of Tbx18þ mesenchyme was additionally
detected within the dorsal mesocardium. Tbx18þ mesenchyme was
more abundant caudally, in proximity of the differentiating sinus horns
myocardium (Figure 2Ba–d) and extended cranially up to the pulmonary
ridges (Figure 2Ag, h). Remarkably, a corresponding situation could be
detected in E9.5 wt embryos, which presented some Tbx18þ cells within
the loosely arranged dorsal mesocardium at the proepicardial border
(Figure 2Bf, g).
In conclusion, E10.5 Tg hearts, although apparently progressed in de-
velopment, are ‘cast’ into a more immature topological arrangement
that strongly affects venous pole remodelling.
3.3 ANKRD1 Tg hearts present SV defects
By mid-foetal stages, most Tg hearts presented a misshapen sino-atrial
region. Three-dimensional anatomically-based reconstruction outlined
Figure 2 ANKRD1 overexpression affects fine rotation and remodelling in the early myocardium. (A) Abnormal rotation and remodelling in E10.5 Tg
compared to wt embryos, ISH whole mount (a, e) and on sections (b–d, f–h) analysis. Dotted lines in a, e show LA-LV angle in wt (white) and Tg (red); dou-
ble-headed arrow shows cranio-caudal extension of the heart from the LV base to the outflow tract. (b, f) Abnormal shape and position of cardiac chambers,
atrioventricular canal (asterisk), and septum primum (dotted box) in Tg. Red dotted lines in c, d, g, h indicate the myocardium of the pulmonary ridges. Black
arrow indicates the pulmonary pit, misplaced in Tg embryos. Yellow arrowheads indicate Tbx18þ cells within the dorsal mesocardium (dm). (B) Venous
pole organization in E10.5 Tg (a–d) and E9.5 wt (e–g) embryos, ISH on sections (a–d, f, g), and whole mount (e). Red dotted lines delineate the sino-atrial
myocardium. Yellow arrowheads indicate Tbx18þ cells within the dm. Black dotted circle in f’, g highlights the base of the dm where some Tbx18þ cells are
visible, flanking the loosely arranged mesoderm (red asterisks). fg, foregut; pe, proepicardium. See Figure 1 legend for other abbreviations. Scale bar: A,
B= 100 lm.
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the malpositioning of venous inlets, which however drained in the cor-
rect atrial chamber (Figure 3A). Additionally, Tg hearts presented a net-
work of microcanalizations, delineating a fine network of ectopic
connections between the PV and systemic veins, which partially drained
into the vestibular region through small fenestrations (Figure 3Ad, f and
Supplementary material online, Figure S3). These anomalous veno-atrial
connections have been associated to SV defects in humans.29
Anomalous veno-atrial connections were normally accompanied (20/27
embryos) by atrioventricular rotational defects and compressed appear-
ance of the vestibular region (Figure 3Ad and Supplementary material on-
line, Figure S3). However, in a minority of Tg embryos (7/27) SV defects
occurred in the absence of morphogenetic impairment (not shown),
thus indicating higher venous pole sensitivity to increased ANKRD1
expression.
At the early postnatal life, only subtle differences could be detected
between wt and Tg hearts by external anatomical observation
(Figure 3Ba, e), however, SV defects could be clearly outlined histologi-
cally (Figure 3Bb–d, f–h). A misshapen fossa ovalis was also clearly recog-
nizable (Figure 3Bg).
In conclusion, ANKRD1 Tg hearts present SV defects. Fine alterations
in cardiac venous pole remodelling impact both systemic and PV
development, which are closely interwined.30 Our data support the hy-
pothesis that SV defects are likely originated by impaired remodelling of
the sino-atrial myocardium during embryonic development.
To investigate the mechanisms for SV defects, we initially wondered
whether master transcription factors GATA4 and Nkx2.5, functionally as-
sociated to ANKRD1, could be transcriptionally affected in early Tg em-
bryos. qPCR analysis showed that GATA4 and Nkx2.5 mRNA levels were
increased in E10.5 Tg hearts (P< 0.05 for Nkx2.5), however, this differ-
ence was blunted at E14.5 (Figure 4A). These results indicate that very
low ANKRD1 overexpression is sufficient to affect GATA4 and Nkx2.5
transcription, however, exclusively within the short time window of
ANKRD1 nuclear localization. Thus, GATA4-Nkx2.5 transcriptional mod-
ulation could be involved in SV defects onset.
As cardiac remodelling occurs thought the entire foetal period, these
results raise the possibility that additional ANKRD1-mediated mecha-
nisms should account for phenotype progression in Tg hearts, including
altered chamber morphology. ISH analysis of E14.5 Tg hearts did not
show differences in regional distribution of genes which delineate and/or
define myocardial landmarks and compartments, such as Pitx2 (left–right
identity),31 Tbx3 (primary myocardium),32 Nppa, Gja5 (chamber myocar-
dium),32,33 Mlc2v (ventricular myocardium),33 Bmp10 (trabecular
Figure 3 SV defects in mid-foetal and neonatal ANKRD1 Tg hearts. (A) Three-dimensional reconstruction of the sino-atrial region and venous system lu-
men in E13.5 hearts, highlighting anomalous venous pole organization in Tg hearts. Note in d, the canalizations around PV and systemic veins and a com-
pressed shape of the vestibular region; (b, c, e, f) virtual sections at the venous pole. In Tg embryos, the communications between PV and systemic veins
around the vestibular regions define the SV defects. Black lines delineate splanchnopleure. (B) Neonatal hearts, freshly isolated (a, e), and H/E analysis (b–d, f–
h). (c) White arrow indicates atrial malrotation, yellow arrow indicates rounded ventricular apex. (g, h) SV defects in Tg hearts. Confluence of RSCV and PV
at the dorsal atrial wall (asterisk in g) and into the RA (h) are clearly recognizable. Black arrowhead in g indicates the misshapen fossa ovalis. See Figure 1 leg-
end for abbreviations. Scale bar: Aa–f= 100 lm; Ba, b, e, f= 500 lm; Bc, d, g, h= 200lm.
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..myocardium),34 and Tbx18 (SH myocardium)28 (Figure 4B), thus ruling
out late transcriptional effects on myocardial patterning.
3.4 Adult ANKRD1 Tg mice develop
progressive ventricular diastolic
dysfunction
We next investigated the consequences of ANKRD1 overexpression in
adult life. Tg mice were born according to Mendelian ratio, however by
10 months (10M) they presented a reduced viability (88, 5%Tg vs. 96,
9%wt; P< 0.05). Histological analysis uncovered a severely dilated left
atrium in all Tg hearts (Figure 5A). LA thrombi, patent foramen ovale
(PFO), ventricular dilatation, and altered chamber geometry could addi-
tionally be detected as isolated or combined defects (Figure 5A).
Moderate fibrosis was detected in ventricular (Figure 5Am, n), but not
atrial chambers, except for the organized thrombi (Figure 5Ag, h).
Accordingly, TGFb levels and TGFb- activated ERK1/2 phosphoryla-
tion35 were moderately increased in Tg hearts (Supplementary material
online, Figure S4).
We compared wt and Tg cardiac function by echocardiography and
haemodynamic analysis at 2M and 10M (Table 1). Echocardiography indi-
cated preserved LV systolic function (i.e. EF and FS values) in 2 and 10M
Tg mice, and absence of ventricular hypertrophy at 10M. However,
transmitralic flow analysis in 2M mice revealed comparable E/A ratio but
higher DT values in Tg animals, suggesting an initial diastolic dysfunction.
By 10M, remarkably increased E/A ratio and reduced DT value were
found in Tg mice, indicating progression of diastolic dysfunction with ag-
ing. Remarkably increased MPI36 in 10M Tg vs. wt mice supports this
notion.
PV flow analysis revealed the presence of a small late diastolic wave
(d2) in 2M Tg mice (6/8) (Figure 5B), indicating additional blood inflow
into the left atrium, presumably via the identified cavo-pulmonary shunts
Figure 4 Timed transcriptional modulation in ANKRD1 Tg embryos. (A) GATA4 and Nkx2.5 mRNA expression levels in E10.5 (wt = 5, Tg = 4) and E14.5
(wt = 4, Tg = 5) hearts, *P< 0.05, Student unpaired t-test; values are compared to the mean wt level at each stage. (B) ISH analysis shows that molecular pat-
terning is not affected in E14.5 Tg hearts. avn, atrio-ventricular node; icv: inferior caval vein; san, sino-atrial node; for other abbreviations, see Figure 1 legend.
Scale bar: a–h: 20lm; i–r: 10lm.
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(Figure 3B and Figure 5A). We hypothesize that cavo-pulmonary shunts
became haemodynamically significant only in late diastole due to onset
of a temporary pressure gradient which favours the R to L shunt. The d2
wave was no longer detected in 10M Tg, indicating a change in L/R atrial
chamber pressure gradients with age.
At 2M, a wave value was significantly higher in Tg than wt mice, indi-
cating more effective atrial contraction (Table 1 and Figure 5B). s and d
wave values were also higher in Tg than wt mice (Table 1 and Figure 5B),
indicating ventricular systolic compensation according to Frank Starling
law. Comparable a/d ratio indicated similar haemodynamics in 2M wt vs.
Tg mice during atrial systole and ventricular diastole; however, s/d ratio
was <1 in 2M Tg mice, as it occurs in early diastolic dysfunction.37 By
10M, decreased a and s values, as well as s/d and a/d ratio indicated less
effective atrial contraction and very different haemodynamics in Tg vs.
wt mice, underlying a severe diastolic dysfunction and loss in LA contrac-
tility. Doppler visualization confirmed this latter finding. Visual assess-
ment of mitral valve flow did not reveal anomalies in valve functionality,
thus ruling out valvular impairment as the leading cause for diastolic
dysfunction.
Overall, functional analysis indicates that 2M Tg mice present initial
ventricular diastolic dysfunction accompanied by increased atrial
contractility; by 10M, diastolic dysfunction progresses into diastolic HF,
associated to LA enlargement and loss of LA contractility. In line, cardiac
disease marker BNP was also significantly increased in 10M Tg hearts
(Figure 5Ao).
Atrial dilatation and diastolic HF together can lead to pulmonary oe-
dema, whereas diastolic HF can occasionally lead to ventricular fibrilla-
tion. Thrombi formation in 10M Tg mice indicates altered atrial
haemodynamics, possibly caused by HF and/or PFO defects.38 All these
comorbidities can have a fatal outcome, therefore they likely account, as
single or combined events, for the reduced viability in 10M Tg mice.
3.5 Cardiomyocyte contractility is impaired
in ANKRD1 Tg hearts
We tested the hypothesis that impaired cardiomyocyte contractility
could contribute to CHD and adult diastolic dysfunction in Tg hearts.
Isolated myofibrils from mid-foetal, early postnatal, and 10M hearts were
tested for passive tension. Neonatal and 10M myofibrils were addition-
ally tested for active mechanical properties.
Sarcomere length-resting tension (SL-RT) relations (i.e. passive me-
chanical properties) of wt and Tg myofibrils were comparable at E14.5
Figure 5 Adult ANKRD1 Tg hearts analysis. (A) Phenotypic variability in 10M Tg hearts. (a–d) Freshly isolated hearts; (e–n) histological analysis, sino-atrial
(e–h), and ventricular (i–n) regions; H/E (e–g, i–l) and Sirius red (h, m, n) staining. Black arrowhead indicates the enlarged Tg LA, asterisk indicates thrombus.
(e–h) Note in (f) anomalous confluence of PV (red dotted arrow) and RSCV (black arrow) at the dorsal atrial wall. (g) Dotted box indicates PFO, associated
to thrombus formation. (h) Fibrotic infiltration within LA thrombus. (i–l) Dilatation and altered geometry in Tg LV; (m, n) moderate fibrosis in Tg LV. (o)
Western blot analysis of BNP vs. GADPH expression in 10M wt (n= 4) and Tg (n= 5) hearts, representative results and box plot quantification; *P< 0.05,
Student unpaired t-test. Scale bar: a–d= 1 mm, e–g, i–l= 0.5 mm, g–i= 100 lm. B: In vivo analysis. (a, b) PV Doppler flow profile of a representative 2M wt (a)
and Tg (b) mouse. Red arrows indicate d2 wave in Tg. (c, d) Representation of mean PV Doppler flow curves in wt and Tg mice at 2 and 10M. Mean a, s, and
d values are from Table 1. (e, f) Echocardiographic view of a 10M wt (e) and Tg (f) heart. Note strongly enlarged LA in Tg (red line).
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(Figure 6Aa) and 10M (Figure 6Ac), but not in newborns (Figure 6Ab).
Interestingly, neonatal wt myofibrils retained passive properties of foetal
stage, as expected,39 whereas Tg myofibrils presented a functional shift
towards the stiffer phenotype of adult wt (Figure 6Ab, c).
Regarding active mechanical properties (Figure 6Ad), the maximally
calcium activated isometric force value (P0) was significantly higher in
neonatal Tg than wt myofibrils, and comparable to adult wt value.
Kinetics of force rise (kACT) and relaxation (slow and fast kREL) and ten-
sion relaxation parameters (Dslow) were comparable in neonatal Tg and
wt myofibrils. Interestingly, adult wt and Tg myofibrils showed compara-
ble kACT, while force relaxation was clearly impaired in Tg, as shown by
significantly increased Dslow and decreased fast kREL. Thus, Tg myofibrils
present a differential modulation of passive and active contractile prop-
erties during life time, i.e. reduced compliance at neonatal stage and
overall slowed down relaxation at 10M.
We investigated the molecular basis for early functional changes ob-
served in Tg myofibrils. Regulation of passive mechanical properties is
mainly due to modulation of titin compliance either post-
transcriptionally, or at the transcriptional level via alternative splicing.40,41
Here, we tested the hypothesis that titin transcription could be affected
in ANKRD1 Tg hearts. Titin splicing regulation involves N2B/N2BA iso-
forms ratio modulation and N2BA length modification via exons inclu-
sion at the middle Ig and PEVK spring regions.40,41
In E14.5 Tg hearts, the transcripts levels of titin did not show signifi-
cant differences, similar to representative thick, thin and Z band compo-
nents (Figure 6B). The N2B/N2BA isoform ratio was slightly, though not
significantly, increased (Figure 6C). In neonatal Tg hearts, expression of
analysed transcripts were unchanged (Figure 6B). However, N2B/N2BA
ratio was now clearly modified and significantly reduced in Tg samples
(Figure 6C), indicating a transcriptional shift towards the more compliant
N2BA isoform. This result was somehow surprising, since functional
data indicated a reduced compliance in neonatal Tg myofibrils
(Figure 6Ab). Intriguingly, when we performed PCR scanning analysis of
N2BA exon usage within middle Ig and PEVK regions, we found that Tg
hearts used a different exon combination, leading to expression of
shorter, therefore less compliant, N2BA titin isoforms (Figure 6C and
Supplementary material online, Figure S5). Thus, a wide modulation
within titin gene transcription accompanies the biomechanical changes
of neonatal Tg myofibrils.
3.6 Cardiomyocyte organization and
ultrastructure are progressively impaired
in ANKRD1 Tg mice
Having established that ANKRD1 overexpression impairs sarcomeric
function, we next explored the impact of these alterations on cellular or-
ganization. Cardiomyocyte disorganization was visible in Tg hearts from
E10.5 onwards (Figure 7A). Confocal analysis showed that E14.5 Tg cardi-
omyocytes were mostly distorted and presented sarcomeric disaligment
(Figure 7Ai, l, Supplementary material online, Videos S1 and S2). Electron
microscopy analysis of neonatal Tg ventricles confirmed sarcomeric dis-
organization and additionally showed focal areas of myofibrillar disrup-
tion (Figure 7Bf, i). Swollen mitochondria with abnormal cristae
(Figure 7Bi) and rare lipid droplets in the cytoplasm (Figure 7Bf) were also
found. By 10M, ultrastructural disorganization progressed in Tg ven-
tricles, as indicated by the increased myofibril loss, mitochondrial damage
..............................................................................................................................................................................................................................
Table 1 Ecocardiographic (top) and haemodynamic (botton) analysis of wt and ANKRD1 Tg mice at 2 and 10months;
n ¼ number of animal analysed (2M: wt¼ 6 males, 4 females; Tg ¼ 3 males, 5 females; 10M: wt¼ 6 males, 3 females,
Tg ¼ 2 males, 5 females)
Wt 2M (n510) Tg 2M (n5 8) Wt 10M (n5 9) Tg 10M (n5 7) Wt vs. Tg
@2M (P)
Wt vs.
Tg @10M (P)
Wt: 2M vs.
10M (P)
Tg: 2M vs.
10M (P)
LV%EF 56.80 ± 3.64 63.75 ± 4.87 58.25 ± 2.94 63.29 ± 4.03 0.23 0.22 0.87 1
LV%FS 29.40 ± 2.53 34.50 ± 3.39 30.25 ± 1.91 34.43 ± 2.90 0.25 0.20 0.93 1
IVSd – – 1.05 ± 0.05 0.96 ± 0.07 – 0.31 –
IVSs – – 1.48 ± 0.03 1.43 ± 0.05 – 0.56 – –
LVIDd – – 3.89 ± 0.14 3.81 ± 0.15 – 1 – –
LVIDs – – 2.69 ± 0.15 2.50 ± 0.19 – 0.30 – –
LVPWd – – 0.97 ± 0.04 0.94 ± 0.06 – 0.90 – –
LVPWs – – 1.36 ± 0.04 1.15 ± 0.10 – 0.05* –
E/A 2.13 ± 0.21 2.04 ± 0.27 2.06 ± 0.23 3.13 ± 0.57 0.95 0.10 1 0.06
DT 19.05 ± 2.12 23.01 ± 3.12 14.90 ± 1.66 14.26 ± 2.14 0.41 0.79 0.23 0.06
MPI 0.79 ± 0.04 0.80 ± 0.07 0.71 ± 0.04 0.86 ± 0.06 0.89 0.06 0.55 0.45
d 363.20 ± 63.65 507.25 ± 75.27 587.13 ± 121.23 629.43 ± 132.17 0.14 0.86 0.91 0.19
d2 np 298.5 ± 39.90 np np – – – –
a -111.40 ± 13.18 -187.63 ± 30.36 -191.13 ± 71.75 -132.57 ± 37.56 0.03* 0.86 0.91 0.12
s 271.20 ± 13.18 371.88 ± 30.36 311.00 ± 71.75 203.86 ± 37.56 0.17 0.02* 0.41 0.03*
s/d 1.01 ± 0.22 0.66 ± 0.08 0.80 ± 0.22 0.34 ± 0.04 0.45 0.01* 1 0.02*
a/d -0.37 ± 0.05 -0.40 ± 0.07 -0.30 ± 0.06 -0.21 ± 0.03 0.82 0.22 1 0.08
a/s -0.45 ± 0.08 -0.60 ± 0.08 -0.49 ± 0.12 -0.62 ± 0.08 0.12 0.32 0.32 0.67
Values are indicated as mean ± SE. *P<_ 0.05.
LV% EF, LV ejection fraction; LV%FS, LV fractional shortening; IVSd, interventricular septum diastolic thickness; IVSs, interventricular septum systolic thickness; LVIDd, LV internal
diameter, diastolic; LVIDs, LV internal diameter, systolic; LVPWd, LV posterior wall, diastolic; LVPWs, LV posterior wall, systolic; MPI, myocardial performance index; np, not pre-
sent. See text and Supplementary material online, Methods for other abbreviations. Wt vs. Tg data comparison at each stage (2M, 10M) was performed by Mann–Wilcoxon W test;
2M vs. 10M data comparison for each experimental group (wt and Tg) was performed by Wilcoxon signed-rank test.
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Figure 6 Modulation of contractile properties in ANKRD1 Tg hearts. A: functional analysis on isolated myofibrils. (a–c) Average sarcomere length-resting
tension relation of myofibrils from E14.5 (a) newborn (b) and adult (c) hearts; wt, black circle; Tg, red circle. Vertical and horizontal bars are SEM. (d)
Mechanical properties of myofibrils from newborn and adult hearts (myofibrils number in brackets). Dslow, duration of the slow linear phase of relaxation;
kACT, rate constant of force development following maximal Ca
2þ-activation; P0, maximum isometric tension; SL, sarcomere length; Slow-Fast kREL, rate con-
stants of tension relaxation for slow and fast relaxation phases. *P < 0.001, #P< 0.02, Student unpaired t-test. (B) qPCR results of sarcomeric genes expres-
sion in E14.5 and newborn hearts. wt vs. Tg: P> 0.05 for each stage, Student unpaired t-test; values are compared to the mean wt level at each stage. (C)
Titin splice variant analysis. Top: schematic representation of titin N2BA and N2B structure; arrows indicate position of primers used for N2BA combinato-
rial exon analysis, red arrows: regions with differential exon inclusion in newborn wt/Tg. Bottom left: N2B/N2BA isoform ratio analysis. *P< 0.05, Student
unpaired t-test; values are compared to the mean wt level at each stage. Bottom right: PCR amplification of exons 72–80 and exons 137–156 from wt and
Tg hearts (n= 5) results in multiple amplicons (square boxes) of different length. The longest amplicons are mostly detected in wt hearts. Y-axis: amplicons
length (bp); X-axis: count of wt and Tg samples which present the specified amplicon (see Supplementary material online, Figure S5 for original data).
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..and accumulation of lipid droplets. Myofibrillar loss was not detected in
adult Tg LA (Figure 7).
In conclusion, tight regulation of ANKRD1 expression is required for
proper modulation of cardiomyocyte structure and of sarcomeric as-
sembly and stability, from early development to adult life. Impaired em-
bryonic remodelling and contractility in ANKRD1 Tg mice are therefore
underlined by a common cellular basis.
4. Discussion
Here, we have presented the first longitudinal study aiming to assess the
consequences of ANKRD1 myocardial overexpression from develop-
ment to adult stage. Novel findings of our study are: (i) the presence of
SV defects in ANKRD1 Tg mice. To our knowledge, this is the first
mouse model for such CHD. (ii) The pathological phenotype of adult
ANKRD1 Tg hearts in the absence of pharmacological stimuli or
pressure overload. This feature has not been highlighted before,16 possi-
bly because of late appearance of gross cardiac abnormalities. The mech-
anistic link between ANKRD1 overexpression, CHD and adult
cardiomyopathy are hereafter discussed, in relation to ANKRD1 expres-
sion and subcellular localization.
4.1 ANKRD1 expression and
overexpression
We have here shown a discrete sub-compartmentalization of Ankrd1 ex-
pression and dynamic nucleo-sarcomeric localization in the developing
heart, not recognized in previous studies.5,7 The limited time window of
nuclear localization suggests that ANKRD1 can sense ongoing haemody-
namic changes42 and respond by fine tuning its interacting partners
(Figure 8A).
Extreme sensitivity to increased ANKRD1 levels in Tg hearts is there-
fore not surprising. Very low levels of Tg expression in E10.5 Tg hearts
were sufficient for morphological and cellular phenotype onset and for
Figure 7 Impairment of cardiomyocyte organization and ultrastructure in ANKRD1 Tg hearts. (A) Cardiomyocyte organization in embryonic wt and Tg
hearts. H/E analysis at E10.5 (a, f) and confocal analysis of E14.5 RV wall (b, c, g, h), trabeculae (d, i), and atria (e, l); (b, g) bright field and nuclei, merged; (c–e,
h–l) actinin. b, c and g, h are adjacent sections. Scale bar: a, f= 20 lm; b–e, g–l= 10 lm. (B) TEM analysis of neonatal and adult ventricles and of adult atria, at
low (a–c, f–h) and high magnification (d, e, i, l). Red asterisk, focal sarcomeric loss; red arrow, sarcomeric disorganization; double headed arrow, extensive
sarcomeric loss; green asterisk, damaged mitocondria; yellow arrowheads, lipid droplets. Scale bar: a–c, f, h= 5lm; d, e, i, l= 1lm.
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transient GATA4 and Nkx2.5 transcriptional up-regulation. ANKRD1 ex-
pression can in turn be regulated by Nkx2.5 and GATA45,6,9 Thus, our
data suggest a novel in vivo autoregulatory loop for increased GATA4 and
Nkx2.5 transcription, mediated by ANKRD1 binding. We cannot rule
out that GATA4 could be directly involved in Nkx2.5 transcriptional acti-
vation.43 GATA4-ANKRD1 functional interaction can lead to increased
GATA4-mediated sarcomeric gene expression and has been proposed
to contribute to sarcomere homeostasis.9,10 On the other hand,
GATA4 and Nkx2.5 together can co-activate target genes regulating car-
diac development.44 We propose that ANKRD1-mediated GATA4 and
Nkx2.5 transcriptional modulation contributes both to cellular pheno-
type onset and to early abnormal venous pole remodelling, leading to SV
defects (Figure 8B).
The extreme sensitivity to ANKRD1 levels in our Tg mice is in line
with TAPVR occurrence in patients presenting a mild increase in
ANKRD1 transcripts and/or protein stability.4,21 TAPVR and SV defects
present a common feature, i.e. abnormal pulmonary venous connec-
tions: PV are not connected to the left atrium in TAPVR, whereas partial
anomalous PV connections characterize SV defects.45 Our data support
the hypothesis that both diseases can stem from a common develop-
mental defect, i.e. reduced cardiac venous pole remodelling.30,45
The limited time-window of GATA4-Nkx2.5 transcriptional modulation
cannot account for the full, complex phenotypic spectrum of Tg mice.
Dynamic titin isoform alterations in Tg hearts and reduced myofibrillar
compliance accompanied by increased max force in neonatal Tg myofi-
brils1,46,47 (Figure 8B–D), altogether indicate a correlation between in-
creased ANKRD1 levels and titin response. Transgene expression was
exclusively sarcomeric in foetal and neonatal hearts, suggesting that al-
tered ANKRD1 stoichiometry could directly affect titin mechanosensing
properties at these stages. However, as titin compliance can be finely
modulated by ANKRD1 binding,1,48 its mechanosensing properties
could be affected already in early Tg embryos. We cannot additionally
Figure 8 Working model linking ANKRD1 expression, overexpression and cardiac disease. (A) Ankrd1 role in heart development. Heterogeneous
Ankrd1 expression and its dynamic nucleo-sarcomeric sub-localization modulate developmental cardiac remodelling in response to haemodynamics by
finely regulating cardiomyocyte transcription and mechanotransduction; the initially contiguous PV (yellow, dotted lines) and systemic veins (red, dotted
lines) precursors become spatially separated by mid-fetal stage. (B) Temporally distinct transcriptional modulation scored in embryonic and neonatal Tg
hearts (red arrows) and their proposed link with disease onset and early progression at the cellular and organ levels (black arrows). (C and D) Disease onset
and progression in Tg hearts, with the underlying cardiomyocyte defects (C) and myofibrillar functional modifications (D). Embryos: impaired myocardial
remodelling retains the contiguity of the regions where PV and systemic veins precursors are located, thereby causing SV defect. Postnatal life: neonatal Tg
hearts present overt cardiomyocyte structural and functional impairment. Altered A-V haemodynamic cross talk (double headed arrow), due to SV defect
and impaired functionality in Tg cardiomyocytes, initiates a vicious loop that progressively leads to diastolic dysfunction (dd), then heart failure (dHF). (D) Tg
myofibrillar functional properties (compliance, lusitropism and maximal force) present substantial modifications in prenatal and postnatal life, as shown by re-
duced and then increased compliance, progressive reduction of lusitropism, and persistent higher maximal force. Colour code: green, values in Tg myofibrils
comparable to corresponding wt; red: values higher than wt.
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rule out that ANKRD1-GATA4(-Nkx2.5)-mediated cardiomyocyte dis-
organization can contribute to trigger an initial titin response (Figure 8B).
Titin can finely respond to changes in sarcomere stretch by differential
splicing of its spring elements, resulting in either increased or decreased
passive stiffness40,49 and can additionally regulate sarcomere assembly50
and stability41 from development to adult life.40,49,51 Thus, our data sug-
gest that titin-mediated mechanotransduction impairment plays a rele-
vant role in Tg cardiomyocyte phenotype functional modulation
(Figure 8B).
Altogether, our results show that activation of GATA4-Nkx2.5 tran-
scription and titin gene modulation are temporally distinct but integrated
systems of rapid response to changes in ANKRD1 levels and in haemo-
dynamic load.
4.2 ANKRD1 overexpression and cardiac
functional disease
Early postnatal transgenic cardiomyocytes presented signs (functional,
molecular, and ultrastructural changes) of ongoing cardiac disease. They
are likely the result of mechanotransduction impairment, due to changes
in haemodynamic load and increased Tg expression at birth.
Disease progression in postnatal life is triggered by both the cellular/
functional and the anatomical substrates. 2M Tg hearts presented an
early adaptive response, likely triggered by small volume overload due to
the R-L shunt and impaired compliance of ventricular cardiomyocytes
(Figure 8C). Progressively, altered haemodynamics and impaired function-
ality in Tg cardiomyocytes initiate a vicious loop, that peaks to the mal-
adaptive organ response observed at 10M (Figure 8B). Dramatic
worsening of Tg ventricular cardiomyocyte ultrastructure in adult hearts
could be caused by their altered mechanosensing properties combined
to the high workload of ventricular chambers. As a support to our hy-
pothesis, myofibrillar loss was absent in adult Tg LA, in line with its major
function as a reservoir chamber.
Functional analysis demonstrated a significant slowing down in the fast
component of myofibrillar relaxation kinetics in 10M Tg hearts. This find-
ing indicates an impairment in inter-sarcomeric dynamics, likely due to
the altered load conditions.52 Comparable passive properties of 10M wt
and Tg indicated that late diastolic dysfunction is due to impaired ventric-
ular relaxation (lusitropy), not impaired passive stiffness (Figure 8D).
Additional possible contributors to cardiomyocyte dysfunction, such as
altered intracellular Ca2þ dynamics and impaired energetic costs53,54
most likely contribute to the diastolic impairment.
The mechanistic links between ANKRD1 overexpression and car-
diac disease progression can only partially be elucidated. However,
transgene nucleo-sarcomeric sublocalization during postnatal life indi-
cates that ANKRD1 can sense the altered cardiomyocyte status and,
once a certain threshold is reached, can respond by modulating its
interacting partners.
ANKRD1 gain of function mutations have been identified in HCM and
DCM patients.18,19 DCM-associated features are ventricular dilatation,
wall thinning, and reduced systolic function, whereas HCM presents with
normal or increased systolic function and strong variability: a subset of
patients develop HF, a minority further progresses to end stage HF,
which resembles DCM.55 At the organ level, ANKRD1 Tg hearts present
typical features of HCM, i.e. diastolic dysfunction with preserved systolic
functionality and phenotypic variability associated to disease progres-
sion.56 Hypertrophic response, the hallmark of human HCM disease,
was not present in ANKRD1 Tg mice, however, this is a shared character-
istic of Tg mouse models of sarcomere-associated HCM mutations.57,58
Contractile dysfunction plays a central role in cardiomyopathies onset
and progression. Increased contraction is associated to HCM onset,
whereas disruption of sarcomeric function and/or structure has been
suggested as early landmark of DCM.55 ANKRD1 Tg neonatal hearts
presented both features, i.e. increased myofibrils maximal force and an
initial sarcomeric loss (Figure 8C and D). Cardiac disease progression is
characterized by increased cardiomyocyte compliance, which is generally
higher in DCM and end-stage HF, compared to early-stage patients.59,60
In this line, the dynamic alteration of contractile properties in Tg myofi-
brils parallels functional changes observed in human disease.
5. Conclusions and perspectives
Our study defines for the first time a unifying picture for ANKRD1 role
in heart development, CHD and adult cardiomyopathy occurrence. The
complexity and multifactorial components of human disease suggests a
note of caution for any direct extrapolation from animal models to
humans. Phenotypic variability of our Tg mice allows to speculate that
fine modulation of interacting partners and signalling pathways could re-
sult in different disease outcome in humans, as previously proposed.61
Our results open the perspective that gain of function mutations of
ANKRD1 gene could be a prognostic early genetic marker for adult car-
diomyopathy, in addition to congenital malformations, such as SV defects
and TAPVR.
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Acknowledgements
We thank Cinzia Parolini for help and support in animal handling and tis-
sue harvesting, Walter Giuriati for histological analysis, Sandra Furlan and
Marco Sandri for help in data analysis, Marta Murgia for critical reading
of the manuscript and for discussion.
Conflict of interest: none declared.
Funding
This work was supported by European Union’s Horizon 2020 research and
innovation programme under grant agreement no. 777204 (SILICOFCM) to
C.P, University of Insubria (FAR 2016-2018) and Federico Ghidoni Memorial
Fund to F.A., Italian Ministry of Education, University and Research (DOR
2018) to S.A.
References
1. Lun AS, Chen J, Lange S. Probing muscle ankyrin-repeat protein (MARP) structure
and function. Anat Rec 2014;297:1615–1629.
2. Miller MK, Bang M-L, Witt CC, Labeit D, Trombitas C, Watanabe K, Granzier H,
McElhinny AS, Gregorio CC, Labeit S. The muscle ankyrin repeat proteins: cARP,
ankrd2/Arpp and DARP as a family of titin filament-based stress response molecules.
J Mol Biol 2003;333:951–964.
3. Ling SSM, Chen Y-T, Wang J, Richards AM, Liew OW. Ankyrin repeat domain 1 pro-
tein: a functionally pleiotropic protein with cardiac biomarker potential. Int J Mol Sci
2017;18:1362.
4. Badi I, Cinquetti R, Frascoli M, Parolini C, Chiesa G, Taramelli R, Acquati F.
Intracellular ANKRD1 protein levels are regulated by 26S proteasome-mediated deg-
radation. FEBS Lett 2009;583:2486–2492.
5. Zou Y, Evans S, Chen J, Kuo HC, Harvey RP, Chien KR. CARP, a cardiac ankyrin re-
peat protein, is downstream in the Nkx2-5 homeobox gene pathway. Development
1997;124:793–804.
ANKRD1 role in heart development and disease 13
D
ow
nloaded from
 https://academ
ic.oup.com
/cardiovascres/advance-article-abstract/doi/10.1093/cvr/cvz291/5613185 by U
N
IVER
SITA D
I FIR
EN
ZE D
IPAR
TIM
EN
TO
 D
I PED
IATR
IA user on 08 January 2020
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
6. Kuo H, Chen J, Ruiz-Lozano P, Zou Y, Nemer M, Chien KR. Control of segmental
expression of the cardiac-restricted ankyrin repeat protein gene by distinct regula-
tory pathways in murine cardiogenesis. Development 1999;126:4223–4234.
7. Jeyaseelan R, Poizat C, Baker RK, Abdishoo S, Isterabadi LB, Lyons GE, Kedes L. A
novel cardiac-restricted target for doxorubicin. CARP, a nuclear modulator of gene
expression in cardiac progenitor cells and cardiomyocytes. J Biol Chem 1997;272:
22800–22808.
8. Bang ML, Mudry RE, McElhinny AS, Trombita´s K, Geach AJ, Yamasaki R, Sorimachi H,
Granzier H, Gregorio CC, Labeit S. Myopalladin, a novel 145-kilodalton sarcomeric
protein with multiple roles in Z-disc and I-band protein assemblies. J Cell Biol 2001;
153:413–427.
9. Chen B, Zhong L, Roush SF, Pentassuglia L, Peng X, Samaras S, Davidson JM, Sawyer
DB, Lim CC. Disruption of a GATA4/Ankrd1 signaling axis in cardiomyocytes leads
to sarcomere disarray: implications for anthracycline cardiomyopathy. Capogrossi
MC, ed. PLoS One 2012;7:e35743.
10. Zhong L, Chiusa M, Cadar AG, Lin A, Samaras S, Davidson JM, Lim CC. Targeted in-
hibition of ANKRD1 disrupts sarcomeric ERK-GATA4 signal transduction and abro-
gates phenylephrine-induced cardiomyocyte hypertrophy. Cardiovasc Res 2015;106:
261–271.
11. Aihara Y, Kurabayashi M, Saito Y, Ohyama Y, Tanaka T, Takeda S, Tomaru K,
Sekiguchi K, Arai M, Nakamura T, Nagai R. Cardiac ankyrin repeat protein is a novel
marker of cardiac hypertrophy: role of M-CAT element within the promoter.
Hypertension 2000;36:48–53.
12. Wei Y-J, Cui C-J, Huang Y-X, Zhang X-L, Zhang H, Hu S-S. Upregulated expression
of cardiac ankyrin repeat protein in human failing hearts due to arrhythmogenic right
ventricular cardiomyopathy. Eur J Heart Fail 2009;11:559–566.
13. Kempton A, Cefalu M, Justice C, Baich T, Derbala M, Canan B, Janssen PML, Mohler
PJ, Smith SA. Altered regulation of cardiac ankyrin repeat protein in heart failure.
Heliyon 2018;4:e00514.
14. Bang M-L, Gu Y, Dalton ND, Peterson KL, Chien KR, Chen J. The muscle ankyrin re-
peat proteins CARP, Ankrd2, and DARP are not essential for normal cardiac devel-
opment and function at basal conditions and in response to pressure overload. Xu
X, ed. PLoS One 2014;9:e93638.
15. Shen L, Chen C, Wei X, Li X, Luo G, Zhang J, Bin J, Huang X, Cao S, Li G, Liao Y.
Overexpression of ankyrin repeat domain 1 enhances cardiomyocyte apoptosis by
promoting p53 activation and mitochondrial dysfunction in rodents. Clin Sci 2015;
128:665–678.
16. Song Y, Xu J, Li Y, Jia C, Ma X, Zhang L, Xie X, Zhang Y, Gao X, Zhang Y, Zhu D.
Cardiac ankyrin repeat protein attenuates cardiac hypertrophy by inhibition of ERK1/
2 and TGF-b signaling pathways. Hirsch E, ed. PLoS One 2012;7:e50436.
17. Arimura T, Bos JM, Sato A, Kubo T, Okamoto H, Nishi H, Harada H, Koga Y, Moulik
M, Doi YL, Towbin JA, Ackerman MJ, Kimura A. Cardiac ankyrin repeat protein gene
(ANKRD1) mutations in hypertrophic cardiomyopathy. J Am Coll Cardiol 2009;54:
334–342.
18. Duboscq-Bidot L, Charron P, Ruppert V, Fauchier L, Richter A, Tavazzi L, Arbustini
E, Wichter T, Maisch B, Komajda M, Isnard R, Villard E; EUROGENE Heart Failure
Network. Mutations in the ANKRD1 gene encoding CARP are responsible for hu-
man dilated cardiomyopathy. Eur Heart J 2009;30:2128–2136.
19. Moulik M, Vatta M, Witt SH, Arola AM, Murphy RT, McKenna WJ, Boriek AM, Oka
K, Labeit S, Bowles NE, Arimura T, Kimura A, Towbin JA. ANKRD1, the gene encod-
ing cardiac ankyrin repeat protein, is a novel dilated cardiomyopathy gene. J Am Coll
Cardiol 2009;54:325–333.
20. Acquati F, Russo A, Taramelli R, Tibiletti MG, Taborelli M, Camesasca C, Papa M.
Nonsyndromic total anomalous venous return associated with a de novo transloca-
tion inolving chromosomes 10 and 21 t(10; 21)(q23.1; q11.2). Am J Med Genet 2000;
95:285–286.
21. Cinquetti R, Badi I, Campione M, Bortoletto E, Chiesa G, Parolini C, Camesasca C,
Russo A, Taramelli R, Acquati F. Transcriptional deregulation and a missense muta-
tion define ANKRD1 as a candidate gene for total anomalous pulmonary venous re-
turn. Hum Mutat 2008;29:468–474.
22. Correa-Villase~nor A, Ferencz C, Boughman JA, Neill CA. Total anomalous pulmonary
venous return: familial and environmental factors. The Baltimore-Washington Infant
Study Group. Teratology 1991;44:415–428.
23. Subramaniam A, Jones WK, Gulick J, Wert S, Neumann J, Robbins J. Tissue-specific
regulation of the alpha-myosin heavy chain gene promoter in transgenic mice. J Biol
Chem 1991;266:24613–24620.
24. Piroddi N, Belus A, Eiras S, Tesi C, J van der V, Poggesi C, Stienen G. No direct effect
of creatine phosphate on the cross-bridge cycle in cardiac myofibrils. Pflugers Arch
2006;452:3–6.
25. Colomo F, Piroddi N, Poggesi C, G Te K, Tesi C. Active and passive forces of iso-
lated myofibrils from cardiac and fast skeletal muscle of the frog. J Physiol 1997;500:
535–548.
26. Scellini B, Piroddi N, Flint GV, Regnier M, Poggesi C, Tesi C. Impact of tropomyosin
isoform composition on fast skeletal muscle thin filament regulation and force devel-
opment. J Muscle Res Cell Motil 2015;36:11–23.
27. de Lange FJ, Moorman AF, Anderson RH, Ma¨nner J, Soufan AT, de Gier-de Vries C,
Schneider MD, Webb S, van den Hoff MJ, Christoffels VM. Lineage and morphoge-
netic analysis of the cardiac valves. Circ Res 2004;95:645–654.
28. Christoffels VM, Mommersteeg MT, Trowe MO, Prall OW, de Gier-de Vries C,
Soufan AT, Bussen M, Schuster-Gossler K, Harvey RP, Moorman AF, Kispert A.
Formation of the venous pole of the heart from an Nkx2-5-negative precursor popu-
lation requires Tbx18. Circ Res 2006;98:1555–1563.
29. Tretter JT, Chikkabyrappa S, Spicer DE, Backer CL, Mosca RS, Anderson RH, Bhatla
P. Understanding the spectrum of sinus venosus interatrial communications. Cardiol
Young 2017;27:418–426.
30. G van den B, Moorman A. Development of the pulmonary vein and the systemic ve-
nous sinus: an interactive 3D overview. PLoS One 2011;6:e22055.
31. Campione M, Ros MA, Icardo JM, Piedra E, Christoffels VM, Schweickert A, Blum M,
Franco D, Moorman A. Pitx2 expression defines a left cardiac lineage of cells: evi-
dence for atrial and ventricular molecular isomerism in the iv/iv mice. Dev Biol 2001;
231:252–264.
32. Hoogaars WM, Tessari A, Moorman AF, de Boer PA, Soufan AT, Campione M,
Christoffels VM. The transcriptional repressor Tbx3 delineates the developing cen-
tral conduction system of the heart. Cardiovasc Res 2004;62:489–499.
33. Christoffels VM, Habets PE, Franco D, Campione M, F de J, Lamers WH, Bao ZZ,
Palmer S, Biben C, Harvey RP, Moorman AF. Chamber formation and morphogenesis
in the developing mammalian heart. Dev Biol 2000;223:266–278.
34. Chen H, Shi S, Acosta L, Li W, Lu J, Bao S, Chen Z, Yang Z, Schneider MD, Chien
KR, Conway SJ, Yoder MC, Haneline LS, Franco D, Shou W. BMP10 is essential for
maintaining cardiac growth during murine cardiogenesis. Development 2004;131:
2219–2231.
35. Heldin C-H, Moustakas A. Signaling receptors for TGF-b family members. Cold Spring
Harb Perspect Biol 2016;8:a022053.
36. Broberg CS, Pantely GA, Barber BJ, Mack GK, Lee K, Thigpen T, Davis LE, Sahn D,
Hohimer AR. Validation of the myocardial performance index by echocardiography
in mice: a noninvasive measure of left ventricular function. J Am Soc Echocardiogr
2003;16:814–823.
37. Faggiano P, Vizzardi E, Pulcini E, Maffeo D, Fracassi F, Nodari S, Dei Cas L. The study
of left ventricular diastolic function by Doppler echocardiography: the essential for
the clinician. Heart Int 2007;3:42.
38. Rigatelli G, Zuin M, Dell’Avvocata F. Atrial fibrillation and patent foramen potentially
share same atrial flow dynamic profile and thrombotic mechanism. Eur J Intern Med
2017;44:e20–e21.
39. Linke W. Sense and stretchability: the role of titin and titin-associated proteins in
myocardial stress-sensing and mechanical dysfunction. Cardiovasc Res 2008;77:
637–648.
40. Granzier HL, Labeit S. The giant protein titin. Circ Res 2004;94:284–295.
41. Linke WA, Hamdani N. Gigantic business. Circ Res 2014;114:1052–1068.
42. Gui Y-H, Linask KK, Khowsathit P, Huhta JC. Doppler echocardiography of normal
and abnormal embryonic mouse heart. Pediatr Res 1996;40:633–642.
43. Brewer AC, Alexandrovich A, Mjaatvedt CH, Shah AM, Patient RK, Pizzey JA. GATA
factors lie upstream of Nkx 2.5 in the transcriptional regulatory cascade that effects
cardiogenesis. Stem Cells Dev 2005;14:425–439.
44. McCulley DJ, Black BL. Transcription factor pathways and congenital heart disease.
Curr Top Dev Biol 2012;253–277.
45. Butts RJ, Crean AM, Hlavacek AM, Spicer DE, Cook AC, Oechslin EN, Anderson
RH. Veno-venous bridges: the forerunners of the sinus venosus defect. Cardiol Young
2011;21:623–630.
46. Elhamine F, Radke MH, Pfitzer G, Granzier H, Gotthardt M, Stehle R. Deletion of the
titin N2B region accelerates myofibrillar force development but does not alter relax-
ation kinetics. J Cell Sci 2014;127:3666–3674.
47. Sequeira V, Velden J. V D. The Frank–Starling Law: a jigsaw of titin proportions.
Biophys Rev 2017;9:259–267.
48. Zhou T, Fleming JR, Franke B, Bogomolovas J, Barsukov I, Rigden DJ, Labeit S,
Mayans O. CARP interacts with titin at a unique helical N2A sequence and at the do-
main Ig81 to form a structured complex. FEBS Lett 2016;590:3098–3110.
49. Anderson BR, Granzier HL. Titin-based tension in the cardiac sarcomere:
molecular origin and physiological adaptations. Prog Biophys Mol Biol 2012;110:
204–217.
50. Walker JS, Tombe PP. D. Titin and the developing heart. Circ Res 2004;94:860–862.
51. Opitz CA, Leake MC, Makarenko I, Benes V, Linke WA. Developmentally regulated
switching of titin size alters myofibrillar stiffness in the perinatal heart. Circ Res 2004;
94:967–975.
52. Poggesi C, Tesi C, Stehle R. Sarcomeric determinants of striated muscle relaxation
kinetics. Pflugers Arch 2005;449:505–517.
53. Borlaug BA, Kass DA. Mechanisms of diastolic dysfunction in heart failure. Trends
Cardiovasc Med 2006;16:273–279.
54. Lopes LR, Elliott PM. A straightforward guide to the sarcomeric basis of cardiomyop-
athies. Heart 2014;100:1916–1923.
55. Garfinkel AC, Seidman JG, Seidman CE. Genetic pathogenesis of hypertrophic and di-
lated cardiomyopathy. Heart Fail Clin 2018;14:139–146.
56. J van der V, Ho CY, Tardiff JC, Olivotto I, Knollmann BC, Carrier L. Research priori-
ties in sarcomeric cardiomyopathies. Cardiovasc Res 2015;105:449–456.
57. Moore RK, Grinspan LT, Jimenez J, Guinto PJ, Ertz-Berger B, Tardiff JC. HCM-linked
D160E cardiac troponin T mutation causes unique progressive structural and molec-
ular ventricular remodeling in transgenic mice. J Mol Cell Cardiol 2013;58:188–198.
14 N. Piroddi et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/cardiovascres/advance-article-abstract/doi/10.1093/cvr/cvz291/5613185 by U
N
IVER
SITA D
I FIR
EN
ZE D
IPAR
TIM
EN
TO
 D
I PED
IATR
IA user on 08 January 2020
..
..
..
..
..
..
..58. Michele DE, Gomez CA, Hong KE, Westfall MV, Metzger JM. Cardiac dysfunction in
hypertrophic cardiomyopathy mutant tropomyosin mice is transgene-dependent, hy-
pertrophy-independent, and improved by beta-blockade. Circ Res 2002;91:255–262.
59. van Heerebeek L, Borbe´ly A, Niessen HW, Bronzwaer JG, van der Velden J, Stienen
GJ, Linke WA, Laarman GJ, Paulus WJ. Myocardial structure and function differ in
systolic and diastolic heart failure. Circulation 2006;113:1966–1973.
60. Vikhorev P, Vikhoreva N. Cardiomyopathies and related changes in contractility of
human heart muscle. Int J Mol Sci 2018;19:2234.
61. Lange S, Gehmlich K, Lun AS, Blondelle J, Hooper C, Dalton ND, Alvarez EA, Zhang
X, Bang M-L, Abassi YA, Remedios CD, Peterson KL, Chen J, Ehler E. MLP and
CARP are linked to chronic PKCa signalling in dilated cardiomyopathy. Nat Commun
2016;7:12120.
Translational perspective
Increased ANKRD1 levels linked to gain of function mutations have been correlated to total anomalous pulmonary venous return (TAPVR) and adult
cardiomyopathy in humans. Myocardial-overexpressing ANKRD1 mouse lines are born with congenital sinus venosus (SV) defect and progressively
develop diastolic dysfunction with preserved EF, which evolves into heart failure. Our data indicate that impaired embryonic remodelling and adult
heart dysfunction stem from a common ground of initial cardiomyocyte defects, which are exacerbated postnatally. Our results open the perspective
that gain of function mutations of ANKRD1 gene could be a prognostic early genetic marker for adult cardiomyopathy, in addition to selective congen-
ital malformations such as SV defects and TAPVR.
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